Novo Nordisk A/S (NVO)
125.79
-0.37
(-0.29%)
USD |
NYSE |
Apr 25, 16:00
126.45
+0.66
(+0.52%)
After-Hours: 20:00
Novo Nordisk Free Cash Flow (Quarterly): -1.065B for Dec. 31, 2023
Free Cash Flow (Quarterly) Chart
Historical Free Cash Flow (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | -1.065B |
| September 30, 2023 | 4.425B |
| June 30, 2023 | 3.197B |
| March 31, 2023 | 3.607B |
| December 31, 2022 | 534.67M |
| September 30, 2022 | 2.374B |
| June 30, 2022 | 2.894B |
| March 31, 2022 | 3.289B |
| December 31, 2021 | -817.54M |
| September 30, 2021 | 3.025B |
| June 30, 2021 | 3.787B |
| March 31, 2021 | 1.582B |
| December 31, 2020 | -2.116B |
| September 30, 2020 | 2.088B |
| June 30, 2020 | 3.381B |
| March 31, 2020 | 1.224B |
| December 31, 2019 | 361.95M |
| September 30, 2019 | 2.093B |
| June 30, 2019 | 1.833B |
| March 31, 2019 | 1.043B |
| December 31, 2018 | 614.42M |
| September 30, 2018 | 1.272B |
| June 30, 2018 | 2.084B |
| March 31, 2018 | 1.131B |
| December 31, 2017 | 253.41M |
| Date | Value |
|---|---|
| September 30, 2017 | 1.917B |
| June 30, 2017 | 1.292B |
| March 31, 2017 | 1.488B |
| December 31, 2016 | 1.205B |
| September 30, 2016 | 1.851B |
| June 30, 2016 | 1.959B |
| March 31, 2016 | 936.48M |
| December 31, 2015 | 1.029B |
| September 30, 2015 | 1.620B |
| June 30, 2015 | 1.593B |
| March 31, 2015 | 501.18M |
| December 31, 2014 | 1.039B |
| September 30, 2014 | 1.914B |
| June 30, 2014 | 1.330B |
| March 31, 2014 | 599.92M |
| December 31, 2013 | 810.97M |
| September 30, 2013 | 958.68M |
| June 30, 2013 | 1.109B |
| March 31, 2013 | 1.093B |
| December 31, 2012 | 151.91M |
| September 30, 2012 | 1.108B |
| June 30, 2012 | 1.064B |
| March 31, 2012 | 886.23M |
| December 31, 2011 | 458.26M |
| September 30, 2011 | 1.311B |
Free Cash Flow Definition
Free cash flow measures the amount of cash left over from a time period after all operational and working capital payments are made. Free cash flow is an important metric because it allows you to view the amount actual cash is available to the company. Free cash flow is also commonly used in valuation calculations like the discounted cash flow valuation model.
Free Cash Flow (Quarterly) Range, Past 5 Years
-2.116B
Minimum
Dec 2020
4.425B
Maximum
Sep 2023
1.879B
Average
2.093B
Median
Sep 2019
Free Cash Flow (Quarterly) Benchmarks
| Amgen Inc | 289.00M |
| AstraZeneca PLC | 1.434B |
| Sanofi SA | -- |
| Viking Therapeutics Inc | -6.134M |
| Evaxion Biotech AS | -- |